Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

University of Paris Diderot. Saint-Louis Hospital. Department of Infectious Diseases. Paris, France.
Fundación Huesped. Buenos Aires, Argentina.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
San Raffaele University. Vita-Salute. Milan, Italy.
Anthony Mills MD Inc. Los Angeles, CA, USA.
University of Alabama at Birmingham. Division of Infectious Diseases. Birmingham, AL, USA.
Chiang Mai University. Department of Medicine. Chiang Mai, Thailand.
University Health Network. Toronto, ON, Canada.
Tibotec BVBA. Beerse, Belgium.
Tibotec Inc. Titusville, NJ, USA.

Abstract

Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected with HIV-1. Rilpivirine, a new non-nucleoside reverse transcriptase inhibitor, has shown similar antiviral efficacy to efavirenz in a phase 2b trial with two nucleoside/nucleotide reverse transcriptase inhibitors. We aimed to assess the efficacy, safety, and tolerability of rilpivirine versus efavirenz, each combined with tenofovir-disoproxil-fumarate and emtricitabine.

Citation

MOLINA, Jean-Michel. et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet, v. 378, p. 238–246, 2011.

DOI

10.1016/S0140-6736(11)60936-7

ISSN

0140-6736

Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/30101

Type

Copyright

Restricted access

Embargo date

2028-08-30

Collections

Share

Statistics

Metadata

Author

Affilliation

Abstract

Citation

DOI

ISSN